Decision Tool Reduces Antidepressant Discontinuation in Depression

Prescribing antidepressants for major depressive disorder frequently involves a frustrating process of trial and error, leading many patients to abandon therapy due to intolerable side effects or a lack of efficacy. To address this challenge, researchers have increasingly explored pharmacogenetic tests and artificial intelligence-driven clinical decision-support systems (software algorithms that analyze patient data to recommend specific treatments) to help personalize medication selection and improve remission rates [1, 2]. While early iterations of these digital tools have demonstrated an ability to accelerate symptom improvement in outpatient settings [3], matching the right patient to the right drug on the first attempt remains a complex clinical hurdle. Additionally, the risk of adverse events and challenging withdrawal symptoms further complicates long-term medication adherence [4, 5]. A newly published multicenter randomized clinical trial evaluating a web-based personalization tool called PETRUSHKA now offers fresh insights into using data-driven methods to keep patients on their prescribed therapies and achieve long-term symptom control [6].